Taoren Honghua Jian improves ferroptosis-mediated myocardial damage following myocardial infarction via Nrf2-dependent enhancement of GPX4/FSP1
Journal of Pharmacy and Pharmacology · 2025
DOI: 10.1093/jpp/rgaf075 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, 2025. Verfasst von Guo-Yong Zhang und 13 weiteren Autor:innen. Beteiligte Einrichtung: School of Traditional Chinese Medicine, Southern Medical University, No. 1023-1063 Shatai South Road, Baiyun District, Guangzhou, Guangdong Province …. Hauptthemen laut MEDLINE: Ferroptosis, NF-E2-Related Factor 2, Myocardial Infarction, Phospholipid Hydroperoxide Glutathione Peroxidase. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Guangdong Basic and Applied Basic Research Foundation, National Natural Science Foundation of China, Shandong Provincial Natural Science Foundation.
Abstract (Originalsprache)
Objectives
Myocardial infarction (MI) remains a leading cause of global mortality, and the inhibition of ferroptosis has cardioprotective potential. Taoren Honghua Jian (TRHHJ) has been used clinically to improve cardiovascular disorders. However, whether TRHHJ inhibits cardiomyocyte ferroptosis and ameliorates myocardial damage after MI requires further investigation. This study aimed to assess the ferroptosis-inhibiting effects of TRHHJ on post-MI myocardial injury and its underlying mechanisms.
Methods
In vivo MI models were established via left anterior descending coronary artery ligation, and the cardioprotective effects of TRHHJ were assessed by echocardiography and histopathology combined with ferroptosis biomarker detection and Nrf2 signaling protein analysis. In vitro, erastin induced ferroptosis in H9C2 cells, and the anti-ferroptotic effects of TRHHJ was evaluated using the MTT assay, ferroptosis markers, and Nrf2 signaling analysis. Mechanistically, Nrf2 inhibitor and knockout mice were used for validation.
Results
TRHHJ suppressed cardiomyocyte ferroptosis, reduced myocardial damage, and improved cardiac function in post-MI mice by activating the Nrf2 signaling pathway in vivo. TRHHJ enhanced cell viability and inhibited erastin-induced ferroptosis in H9C2 cells by increasing Nrf2 level and activating downstream signaling in vitro. Inhibition or knockout of Nrf2 partially abolished these protective effects.
Conclusions
TRHHJ inhibits cardiomyocyte ferroptosis and improves myocardial damage after MI through activation of Nrf2 signaling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Traditional Chinese Medicine, Southern Medical University, No. 1023-1063 Shatai South Road, Baiyun District, Guangzhou, Guangdong Province 510515, China.
- Department of Traditional Chinese Medicine, Nanfang Hospital (ZengCheng Branch), Southern Medical University, No. 28 Chuangxin Avenue, Ningxi Subdistrict, Zengcheng District, Guangzhou, Guangdong Province 510515, China.
- Binzhou Medical University Hospital, No. 661 Huanghe 2nd Road, Bincheng District, Binzhou, Shandong Province 256603, China.
- The Affiliated Traditional Chinese Medicine Hospital, Guangzhou Medical University, No. 95 Tiankun 3rd Road, Tianhe District, Guangzhou, Guangdong Province 510410, China.
- Department of Chinese Traditional Medicine, Medical College, Yanbian University, No. 977 Park Road, Yanji, Jilin Province 133002, China.
- The Tenth Affiliated Hospital of Southern Medical University (Dongguan People's Hospital), No. 78 Wandao Road, Wanjiang Subdistrict, Dongguan, Guangdong Province 523058, China.
ORCID-Profile: Ying-Chun Zhou, Yu-Ting Wu
Förderung
- Guangdong Basic and Applied Basic Research Foundation
- National Natural Science Foundation of China
- Shandong Provincial Natural Science Foundation
- Shandong Province Medical and Health Technology Project
- Dongguan Science and Technology of Social Development Program
Zitieren
APA
Zhang, G. Y., Zhang, F., Xie, L. P., Han, X., Wang, Z. X., Wang, W. L., Peng, Y., Xu, H. L., Xu, T., Pang, M. J., Liu, B., Wang, D., Zhou, Y. C., & Wu, Y. T. (2025). Taoren Honghua Jian improves ferroptosis-mediated myocardial damage following myocardial infarction via Nrf2-dependent enhancement of GPX4/FSP1. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgaf075
Vancouver
Zhang GY, Zhang F, Xie LP, Han X, Wang ZX, Wang WL, et al. Taoren Honghua Jian improves ferroptosis-mediated myocardial damage following myocardial infarction via Nrf2-dependent enhancement of GPX4/FSP1. Journal of Pharmacy and Pharmacology. 2025. doi:10.1093/jpp/rgaf075
BibTeX
@article{Zhang2025,
author = {Zhang, Guo-Yong and Zhang, Feng and Xie, Ling-Peng and Han, Xin and Wang, Zhi-Xin and Wang, Wen-Long and Peng, Yan and Xu, Hong-Lin and Xu, Tong and Pang, Ming-Jie and Liu, Bin and Wang, Dong and Zhou, Ying-Chun and Wu, Yu-Ting},
title = {Taoren Honghua Jian improves ferroptosis-mediated myocardial damage following myocardial infarction via Nrf2-dependent enhancement of GPX4/FSP1},
journal = {Journal of Pharmacy and Pharmacology},
year = {2025},
doi = {10.1093/jpp/rgaf075}
}
EUVIMED